Ozempic vs Wegovy vs Mounjaro: Why None of Them Solve the Real Problem

Ozempic, Wegovy, and Mounjaro are the three biggest names in the GLP-1 weight loss revolution, and if you are trying to choose between them — or wondering whether you need any of them at all — this article is for you. All three drugs work. All three suppress appetite effectively. And all three share the same fundamental flaw: they change your hormones without changing your relationship with food. When you stop taking them — and most women eventually do — your appetite returns to a body that never learned to regulate itself naturally. This is the problem that the French alternative to Ozempic was designed to solve, and it is the reason I believe the conversation about these drugs is missing its most important chapter.

I am Marion. I am not a doctor, and I am not going to tell you whether to take or stop any medication. That decision belongs to you and your physician. What I can offer is a perspective that is conspicuously absent from the Ozempic-vs-Wegovy-vs-Mounjaro debate: the perspective of a culture that has managed appetite naturally for generations, without any of these drugs, at a fraction of the cost and with none of the side effects.

Let me start with the comparison you came for, and then I will tell you what none of these drugs can do.

The Head-to-Head Comparison

Ozempic (semaglutide, 0.5-2mg)

What it is: Originally developed for type 2 diabetes. Contains semaglutide, a synthetic version of the GLP-1 hormone that signals fullness to your brain.

FDA approval: Approved for type 2 diabetes. Widely prescribed off-label for weight management.

Weight loss in trials: 6-12% body weight reduction over 68 weeks in the SUSTAIN trials.

How it works: Weekly injection. Mimics GLP-1 to reduce appetite, slow gastric emptying, and decrease food noise.

Most common side effects: Nausea (up to 20%), vomiting (9%), diarrhea (9%), constipation (5%), abdominal pain.

Monthly cost without insurance: $900-$1,300.

Wegovy (semaglutide, 2.4mg)

What it is: The same molecule as Ozempic but at a higher dose, specifically developed and FDA-approved for chronic weight management.

FDA approval: Approved for weight management in adults with BMI 30+ or BMI 27+ with weight-related conditions.

Weight loss in trials: Approximately 15% body weight reduction over 68 weeks in the STEP trials. The most weight loss of the three drugs.

How it works: Weekly injection. Same mechanism as Ozempic at a higher dose.

Most common side effects: Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%). Higher rates than Ozempic due to higher dose.

Monthly cost without insurance: $1,300-$1,600.

Mounjaro (tirzepatide)

What it is: A dual-action drug that mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), making it the first “twincretin” on the market.

FDA approval: Originally approved for type 2 diabetes. Approved for weight management under the brand name Zepbound.

Weight loss in trials: Up to 22.5% body weight reduction at the highest dose in the SURMOUNT-1 trial — the most dramatic weight loss results of any GLP-1 drug to date.

How it works: Weekly injection. Dual hormone mimicry provides stronger appetite suppression and improved glucose metabolism.

Most common side effects: Nausea (up to 29%), diarrhea (23%), vomiting (12%), constipation (12%), injection site reactions.

Monthly cost without insurance: $1,000-$1,500.

What All Three Have in Common

Beyond the differences in dosing, pricing, and weight loss percentages, these three drugs share something more fundamental than their mechanisms.

They all work only while you take them.

The STEP 1 extension trial for Wegovy showed that participants regained approximately two-thirds of lost weight within one year of stopping. The SURMOUNT-1 extension data for Mounjaro showed similar patterns. The consensus across endocrinology is clear: GLP-1 receptor agonists manage appetite like blood pressure medication manages blood pressure. Stop the drug, lose the effect.

This has enormous implications.

If you start one of these drugs at age 45, you may be looking at 30 or 40 years of weekly injections. At $1,000-$1,600 per month, that is $360,000 to $768,000 over a lifetime. Even with insurance coverage, the copays and the uncertainty of continued coverage make this a precarious long-term plan.

They all cause muscle loss alongside fat loss. A study published in JAMA (2024) found that approximately 40% of weight lost on GLP-1 drugs is lean body mass — muscle and bone. This is particularly concerning for women over 40, who are already losing muscle mass due to hormonal changes. Less muscle means lower metabolism, which means you need even more pharmaceutical support to maintain your weight. It is a cycle that deepens dependency.

None of them teach your body anything. This is the point I find most striking. Ozempic does not train your gut to produce more GLP-1. Wegovy does not rewire your relationship with food. Mounjaro does not teach you to eat slowly or savor your meals. When the drug leaves your system, you are the same person with the same habits, facing the same food environment — but now your natural hormone production may be downregulated from months or years of external supplementation.

This is not an anti-medication argument. These drugs have genuinely improved quality of life for millions of people. But it is an argument for asking a question that the pharmaceutical industry is not incentivized to ask: what if you addressed the root cause instead of the symptom?

The Root Cause These Drugs Cannot Touch

The root cause of the appetite dysregulation that drives most American women to seek GLP-1 medication is not hormonal. It is behavioral, cultural, and psychological.

It is eating quickly — so fast that satiety hormones never reach the brain before the meal is over. French women eat slowly. The research shows this boosts natural GLP-1 by 25-30%.

It is eating without structure — grazing throughout the day, never allowing the body to experience complete hunger-satiety cycles. French women eat three meals at consistent times. This regularity trains the body’s internal appetite clock.

It is eating without pleasure — consuming bland, unsatisfying food that never triggers the hedonic satiety response, leaving the brain perpetually searching for satisfaction. French women eat food that genuinely delights them. Pleasure is the signal that says “enough.”

It is eating with guilt — attaching shame to enjoyment, creating the restriction-binge cycle that amplifies appetite beyond biological need. French women feel no guilt about butter, bread, cheese, or dessert. No forbidden food means no compensatory bingeing.

It is eating without attention — consuming food while scrolling, working, driving, or watching, so the brain never registers that a meal occurred. French women eat at tables, with conversation, with all senses engaged.

These are the reasons American women struggle with appetite. Not because their GLP-1 is defective, but because their eating context suppresses its natural production and overwhelms its signals.

I have written about this extensively: the French approach to life after Ozempic addresses exactly how to build natural appetite regulation, whether you are currently on a GLP-1 drug or have never taken one.

The French Approach: Addressing What Drugs Cannot

The French alternative to Ozempic is not a single food or supplement. It is a complete appetite regulation system built on five pillars that address the root causes of appetite dysregulation:

Natural GLP-1 activation through food. French cuisine is incidentally packed with the most potent natural GLP-1 stimulators: olive oil, lentils, fermented dairy, artichokes, leeks, and polyphenol-rich foods. A traditional French meal does not just taste good — it triggers the same hormonal pathways these drugs target.

Slow eating that maximizes hormone response. With meals lasting 30-45 minutes, French women extract significantly more GLP-1 and PYY from every meal compared to fast eaters consuming the same food. This is free, it has no side effects, and it works every time.

Meal structure that regulates circadian appetite. Three meals, consistent timing, no snacking. This trains the body’s hunger clock so that appetite arrives predictably before meals and resolves completely after them. No drug can replicate this training.

Pleasure-based eating that satisfies the brain. When food is genuinely delicious and eaten with attention, the brain’s dopamine system completes its satisfaction loop. The “food noise” — that constant mental chatter about what to eat next — quiets naturally. This is the side-effect-free equivalent of what women describe on Ozempic: the blissful silence of a brain that is no longer obsessed with food.

A guilt-free food culture that prevents the binge cycle. No restricted foods means no forbidden-fruit effect, no compensatory overeating, no shame spiral. The appetite stays regulated because nothing is disrupting it.

But Can Lifestyle Really Replace Medication?

This is the honest question, and it deserves an honest answer.

For many women: yes. The lifestyle changes described above, practiced consistently, produce natural appetite regulation that is sufficient to maintain a healthy body composition without medication. France’s 17% obesity rate compared to America’s 42% is population-level proof that the system works.

For some women: not entirely, but it changes the equation. If you have severe metabolic dysfunction, insulin resistance, or other medical conditions that impair GLP-1 production, the French approach may not be sufficient on its own. But it can work alongside medication to reduce the dose needed, minimize side effects, and — critically — provide the foundation for eventually tapering off.

For women currently on GLP-1 drugs: it is essential. Whether or not you ever stop your medication, building these habits gives you a safety net. If your insurance changes, if the drug is discontinued, if you simply want to reduce your dose — you have a natural system in place. You are not dependent on a single pharmaceutical lifeline.

The research supports this hybrid approach. A 2023 study in Obesity found that participants who combined GLP-1 medication with structured lifestyle changes retained significantly more weight loss after drug discontinuation than those who relied on medication alone.

What the Pharmaceutical Companies Will Not Tell You

Novo Nordisk (Ozempic and Wegovy) generated $32 billion in revenue in 2024. Eli Lilly (Mounjaro/Zepbound) generated $11 billion from tirzepatide. These are among the most profitable pharmaceutical products in history.

These companies have no financial incentive to tell you that lifestyle changes could reduce your need for their products. They are not villains — they developed effective drugs that help real people. But their business model depends on lifelong usage.

This is why the conversation around GLP-1 drugs is almost exclusively about which drug is “best” and almost never about whether the underlying problem could be addressed differently. I am offering a different framework. Not instead of medication. Alongside it. Before it. After it. The framework that 67 million French women use every day without a prescription.

A Decision Framework for Real Women

If you are standing at the crossroads — medication or lifestyle or both — here is how I would think about it.

Try the French approach first if:

You have not made meaningful changes to meal structure, eating speed, or food quality
Your appetite dysregulation began with, or was worsened by, dieting
You are drawn to a sustainable, long-term approach
You want to avoid side effects and ongoing costs
You are willing to give it 30 days of consistent practice

Consider medication if:

You have tried genuine lifestyle changes consistently for 3+ months without improvement
You have a medical condition (type 2 diabetes, severe insulin resistance) that impairs natural appetite regulation
Your physician recommends it based on your specific health profile
You understand and accept the commitment to ongoing treatment

Combine both if:

You are already on a GLP-1 drug and want to build a safety net for eventual tapering
You want to reduce your medication dose over time
You are experiencing side effects and want to minimize them through complementary lifestyle support
You want the best of both worlds: pharmaceutical support now, natural regulation long-term

What Success Actually Looks Like

Let me tell you what success looks like in the French model, because it is different from what the drug trials measure.

Success is not a number on a scale. It is not a percentage of body weight lost. It is the absence of war.

It is sitting down to lunch and eating what you want without a calculator running in your head. It is finishing a meal and not thinking about food again until the next meal. It is walking past a bakery, deciding you are not hungry, and feeling no emotion about it — no virtue, no deprivation, just information.

It is having a piece of cake at a birthday party and feeling only enjoyment. It is going on vacation and eating whatever the local cuisine offers without anxiety about “getting back on track.” It is realizing, one day, that you have not thought about food between meals in weeks.

This is the daily reality for most French women. It is not because they are lucky or genetically blessed. It is because their eating culture produces this peace automatically — through structure, pleasure, and the complete absence of food morality.

No drug can give you this. Drugs can suppress your appetite. They cannot give you peace.

The Bottom Line

Ozempic, Wegovy, and Mounjaro are powerful tools. They work. For some women, they are medically appropriate and genuinely life-changing. I will never dismiss that.

But the conversation about appetite and weight in America has become dangerously narrow. It has become: “Which drug should I take?” when the prior question — “Why is my appetite dysregulated in the first place, and can I fix the cause?” — goes unasked.

The French answer to that question is not a pill. It is a way of life. It is slow meals, real food, daily walking, structure, pleasure, and peace. It has worked for centuries. It works today. And it is available to you right now, at no cost, with no side effects, and no prescription.

That does not mean it is easy. Changing how you eat is hard. But it is a different kind of hard than being dependent on a $1,300/month injection indefinitely. And at the end of the work, you own the result. It is yours. No pharmaceutical company can take it from you.

Ready to explore the French alternative? Download my free guide: The French Alternative to Ozempic. It walks you through the complete system — natural GLP-1 foods, meal structure, the pleasure principle, and the step-by-step framework — so you can start building natural appetite regulation this week. Whether you are on medication, considering it, or looking for a different path entirely.

Bisous, Marion

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication without consulting your physician. If you are currently taking Ozempic, Wegovy, Mounjaro, or any GLP-1 receptor agonist, discuss any lifestyle changes with your healthcare provider. Individual results vary, and some medical conditions require pharmaceutical intervention.